Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. - Salvi, S; Casadio, V; Conteduca, V; Burgio, S L; Menna, C; Bianchi, E; Rossi, L; Carretta, E; Masini, C; Amadori, D; Calistri, D; Attard, G; et al. (British Journal of Cancer, 2015)